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ABSTRACT
The issue of central venous catheter (CVC) removal in adult patients with candidaemia remains
controversial. Although removal of CVCs has been advocated as an adjunctive strategy for treating
patients with candidaemia, most studies have failed to control for important variables, e.g., the severity
of illness and persistence of neutropenia. Multivariate analysis has failed to identify a significant effect
of CVC removal on the prognosis for patients with candidaemia. A properly designed randomised trial
that controls for confounding variables is necessary to clarify the importance of CVC removal in such
patients. Until this evidence is available, systematic removal of all CVCs in these patients seems not to be
justified.
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The issue of central venous catheter (CVC)
removal in adult patients with candidaemia has
generated extensive discussion in recent years.
Various studies have shown that retention of
vascular catheters colonised with Candida spp. is
associated with prolonged fungaemia [1,2], an
increased risk of metastatic complications [1–3]
and death in adult patients with candidaemia
[3–6]. As a consequence, removal of vascular
catheters has been advocated as an adjunctive
strategy for treating such patients, and particu-
larly for non-neutropenic adults [7,8]. However,
the situation is perhaps not so straightforward.
Most of these studies did not control for impor-
tant confounding variables, e.g., the severity of
illness and persistence of neutropenia [9]. More-
over, CVC removal had a non-significant effect, or
was not evaluated, in many studies that used
multivariate analysis to identify prognostic fac-
tors in adult patients with candidaemia [10–18].
On the contrary, most of these studies have
revealed similar predictors of a poor outcome, in
particular, host factors and aggressive medical
interventions. Caution is therefore needed when
analysing data concerning catheter removal in
candidaemic patients.
The recent paper in CMI by Rodriguez et al. [19]
showed that this debate is far from at an end. The
study failed to demonstrate any benefit of early
CVC removal for patients with candidaemia.
Instead, severity of illness and infection by species
other than Candida parapsilosis were the main
determinants of mortality. Thus, the main ques-
tion to be answered may not be whether early
removal of CVCs can decrease mortality in
patients with candidaemia, but rather, whether
CVC removal has any impact on overall mortal-
ity. As all 172 patients included in the study by
Rodriquez et al. [19] had the CVC removed, this
question could not be addressed.
As no formal protocol exists in our own
institution regarding CVC removal in patients
with candidaemia, a study was conducted
between 1995 and 2003 to examine the impact of
this intervention on the outcome of candidaemia
in adult patients (aged >13 years). In total, 210
patients had candidaemia at Santa Casa Com-
plexo Hospitalar, a 1200-bed Brazilian teaching
hospital. All 210 patients had sepsis at the time
when candidaemia was diagnosed. The analysis
excluded 82 children and 35 adult patients with
Corresponding author and reprint requests: A. C. Pasqualotto,
Educational and Research Centre, Wythenshawe Hospital,
Southmoor Road, M23 9LT, Manchester, UK
E-mail: acpasqualotto@hotmail.com
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases
no CVC in place. Major underlying diseases and
risk-factors in the remaining 93 patients included
solid tumours (n = 40), previous surgery (n = 40)
and diabetes mellitus (n = 20). Neutropenia
occurred in only 12 cases (and was persistent in
six cases). Most (87.1%) of these 93 patients had a
non-tunnelled CVC in place, and 12.9% had an
implanted port. CVCs were removed for 69.9% of
the patients (implanted ports, 83.3%). The median
time for CVC removal was 4.0 days (range
1–50 days). Candidaemia was considered to be
CVC-related in 16 (17.2%) patients. Candida albi-
cans caused 52.7% of infections, followed by
Candida parapsilosis (18.3%) and Candida tropicalis
(17.2%). Overall in-hospital mortality was 62.4%
(58 ⁄ 93); 30 (32.3%) patients died in the 7 days
following candidaemia, and 19 (20.4%) patients
died between days 8 and 30.
Univariate analysis showed an impressive
association between failure to remove the CVC
and mortality. All 28 patients whose CVC was
retained died, in contrast to only 46.2% (30 ⁄ 65) of
patients who had the CVC removed (p <0.001).
Furthermore, patients with a retained CVC clearly
had a more severe disease, in comparison with
those whose CVC was removed. This is illustrated
by the proportion of patients in the intensive care
unit when candidaemia was diagnosed (78.6% vs.
44.6%; p 0.003), and the proportion requiring
mechanical ventilation (71.4% vs. 27.7%;
p <0.001) or vasopressors (50.0% vs. 16.9%;
p 0.001). APACHE II scores of ‡15 occurred in
82.1% and 51.6% (p 0.006) of these patients,
respectively.
However, multivariate analysis indicated that
CVC removal had no impact on overall in-hospital
mortality. Instead, death was associated with
an APACHE II score of ‡15 (p 0.014; OR 3.7,
95% CI 1.31–10.83) and intensive care unit admis-
sion at the time when candidaemia occurred
(p 0.002; OR 5.62, 95% CI 1.93–16.34). These
results are very similar to those observed for
children with candidaemia [20]. Late mortality
(8–30 days) was associated only with a previous
requirement for surgery (p 0.004; OR 5.17,
95% CI 1.67–15.96).
The above study had some differences from
that of Rodriguez et al. [19]. The retrospective
design of the study was its main drawback, and
as its purpose was not to evaluate early vs.
delayed removal of CVCs, patients who died in
the 48-h period after the onset of candidaemia
were not excluded. In addition, the primary
endpoint was defined as overall in-hospital
mortality, not 30-day mortality, which might
explain, at least in part, the higher mortality rate
found in the study. Nevertheless, the results
seem to agree with those of Rodriguez et al. [19]
in that host factors, and mainly the severity of
illness, were the main determinants of mortality
in patients with candidaemia. There was a strong
bias towards higher disease severity in patients
with retained CVCs.
A properly designed randomised clinical trial
that controls for these confounding variables will
clearly be necessary to clarify the importance of
CVC removal in patients with candidaemia. Until
this evidence becomes available, systematic
removal of all CVCs in these patients seems not
to be justified. The subgroup of patients that
would benefit most from this intervention
remains to be identified.
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